Why Your Testosterone Is Still Low Six Weeks After PCT and What Nolvadex Is Actually Doing About It
Low testosterone after PCT is one of the most common and least well-explained situations in post-cycle recovery, and the answer is almost never as simple as most forum posts suggest. If you have finished a Nolvadex-based post-cycle therapy protocol and your bloodwork still shows suppressed testosterone six weeks later, this article explains exactly what is happening at each level of your hormonal axis, what your bloodwork pattern is actually telling you, why Nolvadex works the way it does rather than the way most people assume, and the specific scenarios where a different intervention is required.
Understanding this properly requires a clear picture of how your hormonal axis was suppressed in the first place and how recovery is supposed to unfold, because the most common mistakes in PCT all come from misreading one of those two processes.
How anabolic steroid use suppresses the HPG axis
The hypothalamic-pituitary-gonadal (HPG) axis is the three-gland signalling chain that governs natural testosterone production. The hypothalamus produces gonadotropin-releasing hormone (GnRH) in pulses, which prompts the pituitary to release luteinising hormone (LH) and follicle-stimulating hormone (FSH), which in turn signal the Leydig cells in the testes to produce testosterone.
When exogenous androgens are introduced, the elevated testosterone and oestrogen in the bloodstream feed back negatively on both the hypothalamus and the pituitary. GnRH pulse frequency drops. LH and FSH output from the pituitary falls sharply. With no LH signal arriving at the testes, the Leydig cells stop producing testosterone. A 2022 review published in Therapeutic Advances in Urology by Desai et al. confirmed that anabolic steroid use suppresses the HPG axis completely, with LH and FSH becoming undetectable in most subjects within weeks of starting a cycle. The testes also decrease in volume during this period as a consequence of functional disuse.
This suppression is not a malfunction. It is the body responding logically to what it perceives as a surplus of androgens and oestrogens by reducing its own output. The problem is that when the exogenous source is removed, the axis does not always restart promptly or fully on its own.
Research by Lykhonosov et al. published in Problems of Endocrinology followed male anabolic steroid users through three months of cessation with PCT and found that 20.5% failed to achieve satisfactory HPG axis recovery within that window. The study found a clear correlation between the duration of use, the number of compounds stacked, and the dose used, and the likelihood of poor recovery. This is not a fringe outcome. One in five users in a controlled study did not recover adequately in three months even with PCT.
What Nolvadex does in PCT and what it does not do
This is where the most critical misunderstanding lies. Nolvadex (Tamoxifen Citrate) does not stimulate testosterone production directly. It does not tell the testes to make more testosterone. What it does is block oestrogen receptors specifically at the hypothalamus and pituitary gland, preventing oestrogen from exerting its suppressive effect on GnRH and gonadotropin release.
The practical consequence is that the pituitary interprets the blocked receptors as low oestrogen and responds by increasing LH and FSH output. This is confirmed in a frequently cited study by Vermeulen and Comhaire published in Fertility and Sterility, which found that Tamoxifen at 20mg per day for 10 days in healthy males produced a moderate but significant increase in LH, FSH, testosterone and oestradiol. PubMed records this as one of the earliest clinical demonstrations of Tamoxifen’s gonadotropin-stimulating effect in males, comparable to 150mg of clomiphene citrate in terms of LH response, but without the LH-blunting effect that Clomid produces on prolonged use.
The mechanism is indirect. Nolvadex does not bypass the axis. It works by restoring the conditions that allow the axis to function, which means the axis itself needs to be capable of responding. When the axis is slow to respond, it is not evidence that Nolvadex is failing. It is evidence that one or more levels of the axis need more time or additional support.
Tamoxifen also has a half-life of five to seven days and accumulates in tissue, which means it takes seven to ten days of daily dosing before plasma concentrations stabilise and full receptor occupancy at the hypothalamus and pituitary is achieved. Users who run bloodwork in the first two weeks of PCT are measuring a system still building to therapeutic effect, not a system that has had a fair chance to recover.
Why testosterone is still low after PCT in most cases
There are four distinct reasons why post-PCT testosterone stays low, each with a different bloodwork pattern and a different appropriate response.
The ester had not fully cleared before PCT began
Starting Nolvadex while a long-acting ester is still active in the bloodstream renders PCT largely ineffective for the duration of that overlap. If total testosterone remains elevated from the cycle, the testes have no reason to restart production regardless of what signals the pituitary is sending.
Testosterone Enanthate has an active life of approximately 10 to 14 days. Testosterone Cypionate is similar. Both require a minimum two-week clearance window before PCT should begin. Nandrolone Decanoate, which has a longer ester, requires three weeks. Users who start PCT at day seven or ten after their last injection of a long-ester compound are not running effective PCT. They are running Nolvadex alongside still-active exogenous testosterone, which achieves very little.
The axis is suppressed but recovering
The most common post-PCT bloodwork pattern is low total testosterone with low or sluggish LH and FSH. This means the HPG axis is still suppressed at the hypothalamic or pituitary level. Nolvadex is working, but the axis is responding slowly, which is expected after heavier, longer or more complex cycles.
A 2023 scoping review published in Drug and Alcohol Dependence by Smit et al. found that near-complete testosterone recovery is seen over months after AAS cessation, and complete gonadotropin recovery is expected over three to six months in most cases. The key word is months, not weeks. A four-week PCT with Nolvadex initiates recovery. It does not complete it. If bloodwork at the end of four weeks shows LH and FSH rising from their suppressed baseline, even if total testosterone is still low, that is evidence of recovery in progress, not evidence of failure.
The appropriate response in this scenario is to extend the Nolvadex course by two to four weeks and retest rather than stopping and assuming the PCT failed.
The testes are not responding to LH stimulation
A less common but clinically important pattern is rising LH and FSH with testosterone that remains significantly below baseline. This indicates the signalling from the pituitary is restored but the testes themselves are not responding adequately to the LH signal. This is a testicular responsiveness issue rather than a hypothalamic or pituitary problem, and it is more common after long cycles, cycles that included compounds with direct testicular toxicity, or in users who experienced significant testicular atrophy during the cycle.
Nolvadex alone cannot address this pattern because the problem is not oestrogen receptor blockade at the brain. It is the inability of the testes to respond to the gonadotropin signal that Nolvadex has restored. Intex Pharma HCG 5000IU directly stimulates Leydig cell activity by mimicking LH at the testicular level, bypassing the pituitary entirely. A two to three week course of HCG followed by a further course of Nolvadex is the appropriate intervention for this pattern.
A study published in the Journal of Clinical Endocrinology and Metabolism by Rasmussen et al. in 2020 confirmed that suppressed testicular function from androgen abuse is effectively fully reversible but that recovery takes between six and eighteen months in many cases, with possible cumulative effects depending on the duration and degree of prior use. This timeline is important context for users who expect their bloodwork to normalise within weeks of a four-week PCT course.
Total testosterone is normal but free testosterone is low
This pattern is frequently misinterpreted and causes unnecessary concern. If total testosterone returns to the reference range but symptoms of low testosterone persist, the issue is often SHBG rather than production. Sex hormone-binding globulin binds testosterone in the bloodstream and makes it unavailable for androgen receptor activity. Only free testosterone that is unbound to SHBG or albumin is biologically active.
Post-cycle SHBG can remain elevated for weeks after total testosterone normalises, leaving insufficient free testosterone available even when the production number looks adequate. This resolves naturally as the hormonal environment stabilises in the weeks and months following PCT. It does not require additional SERM therapy. It requires time and a bloodwork panel that includes free testosterone and SHBG rather than total testosterone alone.
What a properly timed post-PCT bloodwork panel shows
The most useful bloodwork for assessing post-PCT recovery is not taken the day after the last Nolvadex tablet. Due to Tamoxifen’s long half-life and tissue accumulation, it continues to influence gonadotropin levels for a period after the last dose. Testing at this point gives an artificially supported picture rather than a true picture of autonomous HPG function.
The optimal time to run post-PCT bloodwork is four weeks after the last Nolvadex tablet. At minimum, the panel should include total testosterone, free testosterone, LH, FSH, oestradiol and SHBG. A prolactin measurement is also valuable for users who ran Nandrolone or Trenbolone, since elevated prolactin from 19-nor compounds requires a different intervention to suppressed gonadotropins.
The expected pattern of healthy recovery is LH and FSH rising first, followed by total testosterone rising over the subsequent weeks as Leydig cell activity responds to the restored gonadotropin signal. If this sequence is present even if total testosterone has not yet reached the pre-cycle baseline, recovery is on track. If LH, FSH and total testosterone all remain significantly below pre-cycle levels four weeks after the last Nolvadex tablet, that is the point at which extending PCT or adding HCG becomes clinically justified.
Research by Smit and colleagues published in Andrology in 2022 found that when pre-exposure gonadal function was normal, 90% of androgen users had testosterone concentrations return to normal after three months of recovery, and 100% by 12 months.
These numbers are reassuring, but they also clarify that three months is the realistic recovery window for most users, not four weeks.
The role of 19-nor compounds in prolonging recovery
Nandrolone and Trenbolone suppress the HPG axis through a different and more persistent mechanism than testosterone alone. Both compounds are 19-nor steroids, meaning they lack a carbon atom at position 19 on the steroid backbone. This structural difference makes them substantially more suppressive of GnRH and gonadotropins than equivalent testosterone doses, and they also raise prolactin through dopamine receptor binding, which adds an additional hormonal disruption that Nolvadex does not address.
Users who ran Nandrolone or Trenbolone and are seeing poor post-PCT recovery with the low testosterone and low LH and FSH pattern should assess prolactin alongside standard gonadotropin markers. Elevated prolactin suppresses GnRH independently of the oestrogen feedback mechanism that Nolvadex targets. In cases where prolactin is above range, Intex Pharma Cabergoline addresses the dopamine receptor pathway that Nolvadex cannot reach. Continuing Nolvadex while prolactin remains elevated is not ineffective, but it is incomplete.
The Lykhonosov study referenced earlier specifically noted that the type of AAS used was among the strongest predictors of poor HPG axis recovery. This is consistent with the known pharmacological differences between testosterone-based and 19-nor-based suppression.
When to seek clinical support
The large majority of post-cycle recoveries that are struggling at the six-week mark do not require medical intervention. They require either an extended PCT course, the addition of HCG for testicular responsiveness, or a prolactin correction if a 19-nor compound was involved.
However, if testosterone, LH and FSH all remain significantly below pre-cycle levels twelve weeks after the last injection and after a complete PCT course, seeking guidance from a UK hormone specialist is the appropriate next step rather than adding further compounds independently. Rasmussen et al. confirmed in JCEM 2020 that suppressed testicular function from androgen abuse is effectively fully reversible in most cases, but the recovery timeline of six to eighteen months means that some users will require clinical support to avoid prolonged hypogonadism.
The key marker that distinguishes normal slow recovery from a recovery that warrants clinical input is the trajectory of LH and FSH over time. Rising LH and FSH, even slowly, indicates the axis is functioning autonomously and testosterone will follow. Flat or falling LH and FSH three months after the last injection despite completed PCT indicates a problem that self-administered SERM therapy alone may not resolve.
Summary
Low testosterone after PCT is common, clinically documented and in most cases a normal part of the recovery timeline rather than evidence that PCT failed. The three things most worth checking are whether PCT was timed correctly relative to ester clearance, what the LH and FSH pattern looks like relative to total testosterone, and whether a 19-nor compound was used that may have elevated prolactin independently of the oestrogen feedback mechanism Nolvadex targets.
Intex Pharma Nolvadex is the appropriate first-line intervention for HPG axis recovery after most cycles because it addresses the primary suppression mechanism at the hypothalamic and pituitary level. Its limitations are specific and predictable. When those limitations apply, the appropriate additions are equally specific: HCG for testicular responsiveness, Cabergoline for prolactin elevation. Understanding which scenario applies requires bloodwork, not guesswork.
Frequently asked questions
How long does testosterone take to recover after PCT?
Most users with normal pre-cycle gonadal function see testosterone return to normal within three months of cessation, with 100% recovery by twelve months in clinical studies. A four-week PCT course with Nolvadex initiates recovery but does not complete it. Bloodwork taken four weeks after the last PCT tablet gives the most useful indication of whether recovery is on track.
Why is my LH normal but testosterone still low after PCT?
Rising LH with low testosterone indicates the pituitary is signalling correctly but the testes are not yet responding adequately. This is a testicular responsiveness issue rather than an HPG axis suppression problem. HCG, which directly stimulates Leydig cell activity by mimicking LH at the testicular level, is the appropriate intervention for this specific bloodwork pattern.
Can Nolvadex PCT fail?
PCT with Nolvadex can underperform in several specific scenarios: starting too early before the long-acting ester clears, running it after a highly suppressive 19-nor cycle without addressing prolactin, not running it for long enough, or not pairing it with HCG when testicular atrophy is significant. Research by Lykhonosov et al. found 20.5% of AAS users failed to achieve satisfactory HPG axis recovery after three months even with PCT, with the strongest predictors being long cycle duration, high doses and stacked compounds.
Should I run HCG before or after Nolvadex for PCT?
HCG is most effective when used either during the cycle to maintain testicular function or in the two weeks immediately after the last injection before Nolvadex begins. This sequence primes the testes for the SERM phase. HCG and Nolvadex should not be run simultaneously because HCG raises oestrogen, which works against the oestrogen receptor blockade that Nolvadex depends on for its mechanism of action.
Does running Nandrolone or Trenbolone make PCT harder?
Yes. Both are 19-nor steroids that suppress the HPG axis more deeply and persistently than testosterone alone. They also raise prolactin through dopamine receptor binding, which Nolvadex does not address. Users who ran these compounds should measure prolactin in their post-PCT bloodwork and consider adding Cabergoline if it is elevated, since prolactin suppresses GnRH independently of the oestrogen feedback mechanism that Nolvadex targets.
What bloodwork should I run after PCT?
Run a full panel four weeks after the last Nolvadex tablet. Include total testosterone, free testosterone, LH, FSH, oestradiol and SHBG as a minimum. Add prolactin if the cycle included Nandrolone or Trenbolone. Rising LH and FSH with testosterone still climbing toward the pre-cycle baseline is the expected healthy recovery pattern. Flat LH and FSH alongside low testosterone at this point indicates the axis is not yet recovering autonomously and warrants extended PCT or clinical review.